Separately, Zacks Investment Research raised Mesoblast from a “sell” rating to a “hold” rating in a report on Tuesday, February 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Mesoblast currently has a consensus rating of “Hold” and a consensus target price of $9.83.
Shares of MESO opened at $3.40 on Tuesday. The stock has a 50-day moving average of $4.14 and a two-hundred day moving average of $4.76. Mesoblast has a one year low of $3.36 and a one year high of $8.85. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.88 and a current ratio of 1.88. The stock has a market cap of $442.31 million, a P/E ratio of -4.47 and a beta of 3.05.
Several hedge funds have recently modified their holdings of the company. Morgan Stanley lifted its holdings in shares of Mesoblast by 16.6% in the 1st quarter. Morgan Stanley now owns 51,715 shares of the company’s stock valued at $428,000 after buying an additional 7,369 shares during the period. Penbrook Management LLC raised its holdings in Mesoblast by 3.8% in the 4th quarter. Penbrook Management LLC now owns 255,850 shares of the company’s stock worth $1,228,000 after purchasing an additional 9,400 shares during the period. JustInvest LLC acquired a new position in Mesoblast in the 4th quarter worth about $53,000. Cambridge Investment Research Advisors Inc. acquired a new position in Mesoblast in the 3rd quarter worth about $66,000. Finally, Cetera Advisor Networks LLC raised its holdings in Mesoblast by 43.1% in the 3rd quarter. Cetera Advisor Networks LLC now owns 36,500 shares of the company’s stock worth $219,000 after purchasing an additional 11,000 shares during the period. 2.72% of the stock is owned by institutional investors and hedge funds.
Mesoblast Company Profile (Get Rating)
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.
- Get a free copy of the StockNews.com research report on Mesoblast (MESO)
- Time to Buy These 3 Oversold Mid-Caps
- Johnson Outdoors Falls On Bleak Outlook
- Institutional Support For Tyson Foods Is Growing
- Littelfuse Stock is Hitting on All Cylinders
- Mattel Stock is Ready to Catch
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.